Relmada Therapeutics, Inc. (RLMD) KPIs and segments

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30

$4.16−0.27 (-6.09%)

Close on Nov 12, 2026Market cap $443.75MP/E –Yield –

KPIs & segments

Operating metrics and segments that drive Relmada Therapeutics's business

Coming soon

This tab will track the numbers specific to Relmada Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.

See a number that looks wrong?